Introduction
============

Bladder cancer (BCa) is the most common cancer of the urinary tract in the United States ([@b1-ol-0-0-8326],[@b2-ol-0-0-8326]). In China, BCa is the malignant tumor of the urinary system with the highest incidence and cancer-associated mortality rate and the incidence of BCa has been increasing in previous years ([@b3-ol-0-0-8326],[@b4-ol-0-0-8326]). Approximately 90% of BCa cases are of bladder urothelial carcinoma (BUC) ([@b5-ol-0-0-8326]). When initially diagnosed, the majority of patients with BCa undergo transurethral resection of the bladder tumor (TURBt) ([@b6-ol-0-0-8326]); however, 50--70% of patients with non-muscle invasive BUC experience disease recurrence following TURBt, 15--25% of whom experience progression to higher disease grades and stages ([@b7-ol-0-0-8326]). Early disease diagnosis and surveillance are necessary to attain better outcomes for patients with BUC ([@b8-ol-0-0-8326]). Currently the standard modalities for detecting BCa are cystoscopy and urine cytology ([@b8-ol-0-0-8326]). Cystoscopy is an invasive procedure with high specificity ([@b8-ol-0-0-8326]). Although urine cytology is non-invasive and has high specificity for detecting carcinoma cells, it lacks sensitivity, particularly for low-grade tumors ([@b8-ol-0-0-8326]). Therefore, it is necessary to find a non-invasive method with high specificity and sensitivity to improve the diagnosis and surveillance of BUC ([@b9-ol-0-0-8326]).

Liquid-based cytology (LBC) has been developed as an alternative to conventional urine cytology. Previous comparative studies have shown that LBC is superior to conventional cytology, as it has a sensitivity and specificity \>90% ([@b10-ol-0-0-8326]--[@b12-ol-0-0-8326]). Additionally, complementary techniques, including DNA, RNA and protein molecular analysis, can be applied to LBC samples, thus allowing the effect of various cancer biomarkers to also be studied ([@b13-ol-0-0-8326],[@b14-ol-0-0-8326]).

In the ongoing search for novel bladder tumor markers, numerous potential markers have been identified; however, their sensitivity and specificity are not high enough to reduce the application of cystoscopies for the detection of bladder carcinoma ([@b9-ol-0-0-8326],[@b15-ol-0-0-8326]). Survivin is a 16.5 kDa protein that acts as a member of the inhibitor of apoptosis proteins (IAP) family and is expressed during embryonic and fetal development ([@b16-ol-0-0-8326]). Survivin is completely undetectable in normal adult tissue, but is prominently expressed in a variety of the most common human cancer types, including those of the lung, colon, pancreas, prostate and breast ([@b17-ol-0-0-8326],[@b18-ol-0-0-8326]). Owing to its substantial upregulation in cancer tissue and its function in carcinogenesis and tumor progression, Survivin is currently proposed to be a possible tumor marker. In BCa, Survivin expression has been observed by immunohistochemistry and may be associated with accelerated incidence of disease recurrence ([@b19-ol-0-0-8326]). Survivin has been suggested to be a promising diagnostic marker for BCa detection owing to its high sensitivity for detection of carcinoma *in situ*, which is frequently missed by cystoscopy and by the majority of other tests ([@b20-ol-0-0-8326]). Smith *et al* ([@b21-ol-0-0-8326]) measured Survivin levels in a group of 138 patients with BCa and reported a sensitivity of 100% and a specificity of 95%, where as Wang *et al* ([@b22-ol-0-0-8326]) reported a sensitivity of 80% and a specificity of 100% in a group of 66 patients with BCa.

At the time of writing, to the best of our knowledge no study has been conducted to investigate the diagnostic efficacy of the combined using of urinary Survivin detection and LBC in the same patients. This preliminary study was therefore undertaken to evaluate the diagnostic values of this combined detection method for BUC.

Patients and methods
====================

### Study subjects

Between January 2012 and December 2013, urine samples from 36 patients with BUC were collected, which were pathologically confirmed following surgery (27 males, 9 females; age range, 41--79 years; mean age 57.34±22.20 years). In total, 26 patients had low-grade (grade I/II) disease and 10 had high-grade (III grade) disease (according to the World Health Organisation 2004 criteria) ([@b23-ol-0-0-8326]). These patients were divided into 19 cases of non-muscle-invasive tumor (Ta-T1) and 17 cases of muscle-invasive tumor (T2-T4) using the Tumor-Node-Metastasis staging system (UICC 2009) ([@b24-ol-0-0-8326]). In the control group, 36 patients diagnosed with non-cancerous urinary tract disease were selected (28 males and 8 females, age range, 40--78 years; 13 cases of benign prostate hyperplasia, 6 of chronic prostatitis, 8 of urinary tract stones, 3 of urinary tract infection, 4 of glandular cystitis, 1 of redundant prepuce and 1 of foreign body of bladder). Fasting morning urine samples were obtained from all subjects. The present study was approved by the ethics committee of Jinling Hospital and each patient provided written informed consent.

### Sample collection

Midstream urine samples (40--50 ml) were obtained from all subjects and were concentrated immediately by centrifugation at 400 × g for 5 min at room temperature (22±1°C). The samples were then stored at −80°C until further processing.

### ELISA

Survivin protein levels were measured in urine with Human Survivin ELISA kit (D10564; Jingmei Biotech Co., Ltd., Shenzhen, China) according to the manufacturers protocol. The absorbance was measured using a microplate reader at 570 nm (Model 680 Microplate Reader; Bio-Rad Laboratories, Inc., Hercules, CA, USA) and the data were recorded. A Survivin concentration that was 2-fold higher than the mean levels of control groups were defined as positive, as previously described ([@b19-ol-0-0-8326]).

### LBC test

The LBC test was performed using an automated liquid-based monolayer cell preparation system (ThinPrep 2000 system; Hologic, Inc., Marlborough, MA, USA). The samples were immersed in Cytolyt (Hologic, Inc., Marlborough, MA, USA) and transferred to a PreservCyt bowl. The cylinder with a filtration membrane was then placed in PreservCyt bowl and was rotated to ensure that the cells were homogeneously distributed. When a vacuum was applied, the erythrocytes and mucus were removed by negative pressure. Thus, only the cells left on the filtration membrane were attached to the slide and then fixed in 95% ethyl alcohol at room temperature. Following fixation for 30 min, smears of specimens were cytologically stained using standard Papanicolaou staining as previously described ([@b25-ol-0-0-8326]). All slides were evaluated routinely by an experienced cytopathologist without any prior knowledge of the immunohistochemical findings.

### Statistical analysis

The results are presented as proportion (%). The sensitivity, specificity and accuracy were calculated for different detection method. Comparison of the results were performed by the χ^2^ test (SPSS 11.0 for Windows; SPSS, Inc., Chicago, IL, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Survivin level is elevated in the urine of patients with BUC

The clinical utility of Survivin at discriminating patients with BUC from individuals with non-cancerous urinary tract disease was analyzed. Urine samples were categorized according to histopathological results. Survivin concentrations in individual urine samples were measured using a commercial ELISA kit. Survivin levels in the urine of BUC and non-cancerous urinary tract disease are demonstrated in [Table I](#tI-ol-0-0-8326){ref-type="table"}. Of the 36 BUC cases, 21 were Survivin-positive. In the non-cancerous urinary tract disease group, only 2 cases were Survivin-positive. The results revealed that urine Survivin concentrations are extremely high in the BUC group compared with the controls. The presence of Survivin was able to discriminate bladder cancer from benign disease.

### Most of BUC cases test positive by LBC

The LBC diagnoses for the 72 cytological samples are summarized in [Table I](#tI-ol-0-0-8326){ref-type="table"}. The cells were uniformly distributed on the glass slides in all cases. The LBC technique provides a clean background with less obscuring inflammatory cells and blood compared with urine cytology ([Fig. 1](#f1-ol-0-0-8326){ref-type="fig"}). Of the 36 cancer cases, 28 were found to be positive by LBC; of the 36 cases in control group, 1 was suspected to be positive.

### The combined use of Survivin detection and LBC has a significantly increased diagnostic sensitivity and accuracy

The results for the combined use of Survivin detection and LBC had also been indicated in the [Table I](#tI-ol-0-0-8326){ref-type="table"}. Of 36 cases in BUC group, 33 were Survivin- and LBC-positive. Compared with Survivin detection or LBC alone, the combined detection method had a slightly lower specificity, but a significantly increased diagnostic sensitivity and accuracy (P\<0.05).

Discussion
==========

An ideal test to monitor BCa should be objective, non-invasive, easy to administer and interpret, and have high sensitivity and specificity. An ideal tumor biomarker should be highly sensitive, specific and accurate ([@b26-ol-0-0-8326]). Ease of performance and low cost are also desirable. It has been reported that Survivin and LBC have utility for the detection of BUC ([@b11-ol-0-0-8326],[@b12-ol-0-0-8326],[@b16-ol-0-0-8326],[@b20-ol-0-0-8326],[@b22-ol-0-0-8326],[@b26-ol-0-0-8326]--[@b36-ol-0-0-8326]).

Urinary levels of Survivin expression at the protein and mRNA levels are associated with BCa presence, higher tumor grade, and advanced pathologic stage ([@b16-ol-0-0-8326]--[@b28-ol-0-0-8326]). Survivin protein levels have been detected previously by nested polymerase chain reaction (nested PCR), immunohistochemical staining, western blot analysis and ELISA, with the nested PCR most widely used ([@b21-ol-0-0-8326],[@b29-ol-0-0-8326],[@b30-ol-0-0-8326]). Smith *et al* ([@b21-ol-0-0-8326]) were the first to evaluate the diagnostic potential of Survivin expression in bladder cancer, using protein and mRNA detection methods. The sensitivity of Survivin as a biomarker was 100%, with a specificity of 95% in a group of 138 patients ([@b21-ol-0-0-8326]). Zhao *et al* ([@b29-ol-0-0-8326]) reported that molecular beacons detected cancerous cells in 28 (80%) of the 35 patients with confirmed BCa. The Survivin mRNA assay for the diagnosis of BCa had only 68.6% sensitivity; however, it did have 100% specificity. Chen *et al* ([@b30-ol-0-0-8326]) found that Immunohistochemical analysis indicated high survivin expression was associated with tumor stage and grade and may present a predictive marker of overall survival in BUC. Zhao *et al* ([@b29-ol-0-0-8326]) reported that Survivin protein expression was detected in 25 (71.4%) of the 35 patients studied. The sensitivity and specificity of ELISA was 54.3 and 68.6%, respectively. In summary, Survivin has been shown to be implicated in the detection of BUC ([@b21-ol-0-0-8326],[@b29-ol-0-0-8326],[@b30-ol-0-0-8326]). The findings indicate that Survivin is a promising urinary molecular marker for BCa early detection and prognosis prediction ([@b21-ol-0-0-8326],[@b29-ol-0-0-8326],[@b30-ol-0-0-8326]). However, the assays above are non-standardized, as none of their performances complied with validation criteria appropriate for analytic techniques and the assays require further innovation and standardization. Eissa *et al* ([@b19-ol-0-0-8326]) reported that qualitative reverse transcription-PCR in 153 samples revealed that the mean rank levels of survivin in the benign and malignant groups were significantly increased by 1.1 and 2.23-fold, respectively, vs. the normal group (P\<0.0001). In the present study, Survivin levels over 2 times of mean value in control group for the sample were defined as positive. Applying this cutoff value, the sensitivity and specificity of urinary survivin was 58.0 and 94.4%, respectively.

Urine cytology, as a diagnosis method, has a reasonable sensitivity for the detection of high-grade urothelial carcinoma (UC); however, it is less sensitive for detecting low-grade tumors ([@b31-ol-0-0-8326]).

LBC have been regarded as an alternative to conventional cytology for the primary screening of BCa owing to its practical advantages, with variable circumstances. The advantages of LBC include: samples have a 'cleaner' background, devoid of blood, mucus and inflammatory cells; LBC uses automated and standardized processing techniques that produces the homogenous distribution and efficient fixation of cells; and the residual biological material can be used for immunohistochemical or other special analyses ([@b32-ol-0-0-8326]--[@b34-ol-0-0-8326]). Several previous reports have demonstrated that LBC is superior to conventional cytology for the identification of BCa ([@b11-ol-0-0-8326],[@b35-ol-0-0-8326],[@b36-ol-0-0-8326]). LBC has a sensitivity and specificity \>90% in non-gynecological specimens ([@b12-ol-0-0-8326]). The present study revealed LBC had a sensitivity of 77.8% and specificity of 97.2%.

To the best of our knowledge, the present study is the first to investigate the diagnostic activity of Survivin and LBC in the same patients with BUC. The results indicated that combined use of urine Survivin and LBC test could significantly improve the diagnosis of BUC. In the present study, the efficacy of this combined test was investigated, which exhibited a sensitivity of 91.7%, specificity of 91.7% and accuracy of 91.7%. Compared with the results of the individual tests, the specificity was decreased, but the sensitivity and accuracy improved significantly. More importantly, this method is non-invasive, economical, simple and precise. Therefore, in future LBC could be used in combination with Survivin detection for more accurate results in the diagnosis of BUC. The research discussed in the current study is limited owing to the small number of samples. Further investigation is therefore required, with a study involving a large number of patients.
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![Representative examples of liquid-based cytology. (A) Bladder urothelial carcinoma cells (magnification, ×200). (B) Single giant malignant cells with hyperchromatic nuclei and irregular nuclear membranes (magnification, ×400).](ol-15-05-7739-g00){#f1-ol-0-0-8326}

###### 

Combined sensitivity, specificity and accuracy for Survivin and LBC in detection of bladder cancer.

  Parameter(s)       Sensitivity, % (n)                                          Specificity, % (n)   Accuracy, % (n)
  ------------------ ----------------------------------------------------------- -------------------- -----------------------------------------------------------
  Survivin           58.0 (21/36)^[a](#tfn2-ol-0-0-8326){ref-type="table-fn"}^   94.4 (34/36)         76.4 (55/72)^[a](#tfn2-ol-0-0-8326){ref-type="table-fn"}^
  LBC                77.8 (28/36)^[a](#tfn2-ol-0-0-8326){ref-type="table-fn"}^   97.2 (35/36)         87.5 (63/72)^[a](#tfn2-ol-0-0-8326){ref-type="table-fn"}^
  Survivin and LBC   91.7 (33/36)^[a](#tfn2-ol-0-0-8326){ref-type="table-fn"}^   91.7 (33/36)         91.7 (66/72)^[a](#tfn2-ol-0-0-8326){ref-type="table-fn"}^

LBC, liquid-based cytology

P\<0.05.
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